Obermatt
See Similar Stocks →

Nxera Pharma

TYO:4565 · JP3431300007
PharmaceuticalsSmall

360

11
EV / EBIT25
Price / Owner Earnings90
Owner Earnings Yield1
Dividend Yield81
Price/Sales60
EV / Gross Profit32
Price/Book79
Return on Capital37
Cash Return on Capital39
Return on Equity34
EBIT Margin22
Gross Profitability35
Accruals64
Owner Earnings Margin28
Sales growth87
Profit Growth17
Long-Term EPS Growth1
Owner Earnings Growth1
Reinvestment13
Price momentum87
Debt load18
Refinancing47
Debt Payback1
Liquidity27
Analyst ratings32
Opinion Changes50
Price Target Upside55
Market mood80
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Nxera Pharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTSE
Founded1990
Employees242
Websitenxera.life
ISINJP3431300007
Last UpdateApr 2, 2026
Index & Theme
ImmunologyGastroenterologyRespiratoryNeurologyCentral Nervous SystemOncologyBiopharmaBiotechnology

Description

Nxera Pharma Co., Ltd. is a science and technology-led biopharmaceutical business whose core activities include drug discovery, drug development, and the commercialization of pharmaceutical products. Business Segments The company operates primarily…

Analysis

Middle-of-the-road

Nxera Pharma Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is fragile. The company scores 6/20 on our value-creation score: not creating value.

What to watch: Some accounting patterns deserve a closer look. The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
75
2023202420252026

All-time high

89

Mar 2026

All-time low

1

Jan 2024

Average rank

38

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
60
46
28
11
Price/Earnings
61
21
28
31
Price/Book
79
67
47
56
Dividend Yield
81
23
19
14
Value (overall)
88
32
26
21

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Nxera Pharma with its peers
Zai Lab
HKG:9688
32
CountryChina
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Yuyu Pharma
KSC:000220
81
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Yungjin Pharm
KSC:003520
34
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
SK Bioscience
KSC:302440
5
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sino Biopharmaceutical
HKG:1177
55
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →